Skip to main content
NEO logo

NEO · Neogenomics Inc

Track NEO — free
$15.61 +0.32 (+2.09%)
Market Cap
$1.98B
Shares
129.39M
Volume · Nov 18 1.09M Avg daily vol (3M) 1.96M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$15.29 Open$15.23 Day$14.86–15.51 52W close$7.19–19.91 Avg vol 30d1.7M Short int13.1M · 10.2% of shares · 6.7d Short vol46% Last earningsOct 28, 2026 DataJan 2020–Nov 2026 Filing10-Q · Oct 28

Up next

Feb 16, 2027 Est · unconfirmed · in 13 wks

Latest documents

2026
Oct 28
Earnings call
Raises Revenue and EBITDA Guidance; Warren Stone Named CEO

Neogenomics reported total revenue of $209 million, up 11% year over year, ahead of its expectations of approximately 10% growth. It raised full-year revenue guidance to $807 to $809 million from $802 to $806 million, and adjusted EBITDA guidance to approximately 60 million from 56 to 58 million. Warren Stone becomes chief executive officer effective January 4, 2027, succeeding Tony Zook, who becomes executive chair.

Read from the first part of this long document
5 source passages
Total revenue grew to $209 million, up 11% year-over-year and ahead of our expectations of approximately 10% growth. we are raising our full-year 26 revenue guidance to a range of $807 to $809 million, up from $802 to $806 million discussed previously we are raising our full year 26 adjusted EBITDA guidance to approximately 60 million versus 56 to 58 million discussed previously effective January 4, 2027, Warren Stone, our current president and chief operating officer, will become chief executive officer of Neogenomics and join our board. I'll support this transition and remain actively involved as our new executive chair. Open the document at this passage
Oct 28
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue growth and gross margin expansion strengthen results

NeoGenomics, Inc. reported that revenue for the three and nine months ended September 30, 2026 increased $21.5 million, or 11.4%, and $60.4 million, or 11.2%, respectively, versus 2025. Gross profit margin was 46.2% and 45.1%, respectively, compared with 42.8% and 43.0%.

Revenue $209.25M ▲ 11.4% Net loss $7.55M
Read from the MD&A section
3 source passages
NeoGenomics, Inc., a Nevada corporation Revenue for the three and nine months ended September 30, 2026 increased $21.5 million or 11.4%, and increased $60.4 million or 11.2%, respectively, as compared to 2025. Gross profit margin for the three and nine months ended September 30, 2026 was 46.2% and 45.1%, respectively, compared to 42.8% and 43.0% in the same periods of 2025. Open the document at this passage
Oct 28
Current report 8-K
Third-quarter revenue rises 11% to $209 million; guidance raised

NeoGenomics reported third-quarter 2026 revenue up 11% to $209 million. It raised full-year 2026 revenue guidance to $807 million to $809 million and expects adjusted EBITDA of approximately $60 million. Warren Stone, President and COO, will become CEO effective January 4, 2027.

Financial results
5 source passages
Consolidated revenue for the third quarter of 2026 was $209 million, an increase of 11% over the same period in 2025. The Company is revising its full-year 2026 guidance, as shown below (in millions). | Consolidated revenue | $727 | $802 | $806 | $807 | $809 | 11% | 11% | | Adjusted EBITDA | $43 | $56 | $58 | Approximately $60 | | Approximately 38% | | Announced planned leadership succession in which Warren Stone, President and COO, will become CEO and Board member effective January 4, 2027. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$787.75M
Trailing 12 months
Net income (TTM)
−$32.30M
Trailing 12 months
Revenue growth YoY
+11.4%
Year over year
Operating margin
-6.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-1.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$241.26M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.1%
Year over year · more shares
Price change (1Y)
+46.9%
Trailing year
Short interest
10.2%
Latest settlement · 6.7 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Oct 28, 2026
Q3 FY26

TL;DR. NeoGenomics delivered 11% total revenue growth, 13% clinical revenue growth, 29% NGS growth and 310-basis-point adjusted gross-margin expansion, while raising full-year revenue and adjusted EBITDA guidance and adding a third Medicare-covered RaDaR ST indication. Non-clinical declines, lower cash, temporary receivables pressure, reimbursement-rate exposure, unreimbursed MRD testing and an $8 million GAAP net loss remain the principal headwinds.

Bullish
  • + Third-quarter total revenue increased 11% to $209 million.
  • + Clinical revenue increased 13% to $195 million, driven by 29% NGS revenue growth.
  • + Full-year 2026 revenue guidance was raised to $807-$809 million from $802-$806 million.
  • + Full-year 2026 adjusted EBITDA guidance was raised to approximately $60 million from $56-$58 million.
  • + Adjusted gross margin expanded 310 basis points to 49%, with adjusted EBITDA of $19 million.
  • + RaDaR ST received Medicare coverage for immunotherapy treatment-response monitoring, marking its third covered indication.
Bearish
  • − Non-clinical revenue declined approximately 10%, or $1.5 million year over year, creating a headwind to total revenue growth.
  • − Cash and cash equivalents were $139 million, down $6 million from the prior quarter.
  • − The revenue-cycle-management platform transition temporarily affected receivables, with normalization expected through the fourth quarter and into early 2027.
  • − Preliminary 2027 reimbursement rates create a low-to-mid-single-digit-million exposure that flows through gross margin and EBITDA.
  • − Unreimbursed MRD testing was expected to remain a gross-margin headwind in the near term.
  • − The company reported a third-quarter GAAP net loss of $8 million.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +17%
above
Price vs 50-day avg −12%
below
RSI (14) 37
neutral
MACD trend Negative
52-week position 64%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −10%
trailing
6-month return +45%
trailing
YTD return +30%
this year
Relative strength +49%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $17 › 200d $13 — 50d above 200d
Institutional flow Accumulating
+11% holders QoQ · +60 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
10.15% of shares out · ▼ -7.6% MoM · 6.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
298 holders — near 3-yr high, broad support
Squeeze score 59
elevated · 0–100
Fundamentals
Weak
Revenue growth +10%
Y/Y
Gross margin 43%
contracting
EPS growth −300%
Y/Y
Free cash flow $-21.8M
Balance sheet $182.2M
net debt
Quant / Vol
risk profile
Very High
Volatility 54%
annualized · 1-yr
Max drawdown −46%
past year
ATR 5.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 1 of last 3
Latest guidance · from the Earnings Call filed Jul 28, 2026
Full year 26 revenue guidance · full year 2026 $802M – $806M
prior FY $727.33M midpoint +10.5% Y/Y
Previous outlook earlier release · from the 8-K filed Feb 17, 2026

Still-open targets the latest release did not restate under the same label.

Net loss per diluted share · Year Ended December 31, 2026 $-0.48 – $-0.38
Adjusted diluted EPS · Year Ended December 31, 2026 $0.16 – $0.21
Prior guidance period ended · from the 8-K filed Oct 5, 2026
Third quarter total revenue · third quarter of 2026 $209M
Guided vs delivered · last 3 settled
Revenue full year
guided $530M – $550M
$509.73M Miss −5.6%
Revenue Q1
guided $118M – $120M
$117.17M Miss −1.5%
Consolidated revenue full-year 2021
guided $482.5M – $487.5M
$484.33M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+17% Bullish
Price vs 50-day avg
−12% Bearish
RSI (14)
37 Neutral
MACD trend
Negative Bearish
52-week position
64% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $17 › 200d $13 — 50d above 200d
Institutional flow Accumulating
+11% holders QoQ · +60 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
10.15% of shares out · ▼ -7.6% MoM · 6.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
298 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $7 Now $15 · 64% Range high $20
vs 200-day avg +17% vs 50-day avg -12%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
NGS revenue growth 28% Q3 2026 —
Adjusted EBITDA non-GAAP $14.47M the three months ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Diagnostics & Research — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
NEO
Neogenomics Inc
this stock
$1.98B +30.0% +10.1% — 10.2%
TMO
Thermo Fisher Scientific Inc.
$256.67B +19.6% +14.5% 36.5 1.3%
DHR
Danaher Corp
$160.81B -0.1% +8.5% 37.4 1.2%
IDXX
Idexx Laboratories Inc
$55.03B +3.2% +10.4% 47.1 3.0%
A
Agilent Technologies, Inc.
$49.99B +30.3% +6.4% 34.9 1.7%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
298
% held
110.1%
Net QoQ
-2.5M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
271
View
Short & Settlement
Short Interest Falling
Shares short
13.1M
Days to cover
6.7d
Change
-1.1M sh
View
Short Volume
Short vol %
46%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
4.8K
Value
$81.0K
As of
Oct 15, 2026
View
Off-Exchange
Off-exchange %
40.5%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Gilbert Cisneros
Amount
$1.0K–$15.0K
Traded
Aug 7, 2026
View
Financials
Financials
Net income (FY)
$-108.0M
EPS diluted
$-0.04
View
Filings
SEC Filings
Latest
10-Q
Filed
Oct 28, 2026
This year
24

NeoGenomics, Inc. reported that revenue for the three and nine months ended September 30, 2026 increased $21.5 million, or 11.4%, and $60.4 million, or 11.2%, respectively, versus 2025. Gross profit margin was 46.2% and 45.1%, respectively, compared with 42.8% and 43.0%.

View
Proposed Sales
Value
$321.5K
Shares
20.0K
Filed
Aug 4, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 1, 2026
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
NeoGenomics to Participate in Upc…
Published
Nov 6, 2026
Upcoming events
2
View

Performance

5D 20D 120D MTD YTD
NEO -9.2% -10.3% +45.3% -12.0% +30.0%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY -5.3% -4.7% +48.8% -8.7% +22.9%
Key facts CIK 1077183 CUSIP 64049M209 13F (30d) 301 filings 280 filers Visit website Investor relations